Verastem Cash on Hand 2011-2022 | VSTM

Verastem cash on hand from 2011 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Verastem Annual Cash on Hand
(Millions of US $)
2021 $100
2020 $141
2019 $76
2018 $250
2017 $87
2016 $81
2015 $110
2014 $93
2013 $101
2012 $57
2011 $48
2010 $4
Verastem Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $106
2021-12-31 $100
2021-09-30 $103
2021-06-30 $108
2021-03-31 $121
2020-12-31 $141
2020-09-30 $180
2020-06-30 $130
2020-03-31 $135
2019-12-31 $76
2019-09-30 $160
2019-06-30 $187
2019-03-31 $212
2018-12-31 $250
2018-09-30 $146
2018-06-30 $169
2018-03-31 $64
2017-12-31 $87
2017-09-30 $60
2017-06-30 $58
2017-03-31 $73
2016-12-31 $81
2016-09-30 $87
2016-06-30 $93
2016-03-31 $100
2015-12-31 $110
2015-09-30 $120
2015-06-30 $132
2015-03-31 $132
2014-12-31 $93
2014-09-30 $93
2014-06-30 $99
2014-03-31 $106
2013-12-31 $101
2013-09-30 $100
2013-06-30 $57
2013-03-31 $67
2012-12-31 $57
2012-09-30 $47
2012-06-30 $39
2012-03-31 $41
2011-12-31 $48
2011-09-30
2011-06-30
2011-03-31
2010-12-31 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.211B $0.002B
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00